

## Hiding in Plain Sight: Functional Neurological Disorders in the News

Stoyan Popkirov, M.D., Timothy R. Nicholson, M.D., Ph.D., Bastiaan R. Bloem, M.D., Ph.D., Hannah R. Cock, M.D., Christopher P. Derry, Ph.D., Roderick Duncan, M.D., Ph.D., Barbara A. Dworetzky, M.D., Mark J. Edwards, Ph.D., Alberto J. Espay, M.D., Mark Hallett, M.D., Anthony E. Lang, M.D., John Paul Leach, M.D., Alexander Lehn, M.D., Aileen McGonigal, M.D., Ph.D., Francesca Morgante, M.D., David L. Perez, M.D., M.M.Sc., Markus Reuber, Ph.D., Mark P. Richardson, Ph.D., Philip Smith, M.D., Maria Stamelou, M.D., Marina A. J. Tijssen, M.D., Michele Tinazzi, M.D., Alan J. Carson, M.D., Jon Stone, Ph.D.

**Objective:** Functional movement and seizure disorders are still widely misunderstood and receive little public and academic attention. This is in stark contrast to their high prevalence and levels of associated disability. In an exploratory observational study, the authors examined whether the relative lack of media coverage of functional neurological disorders is in part due to misidentification in “human interest” news stories.

**Methods:** Thirteen recent news stories from high-impact English-language media outlets that portrayed patients with complex symptoms either attributed to other diagnoses or presented as medical mysteries were identified using online keyword searches. All selected news stories contained video or still images displaying relevant symptoms. Cases were categorized into movement disorders or seizure disorders and were then independently assessed by 10 respective expert raters. For each category, one story of a patient whose symptoms were due to a well-recognized

neurological disease was also included. Both the diagnostic category and the respective confidence level were reported by each rater for each case. The interrater agreement was calculated for each group of disorders.

**Results:** The raters confirmed almost unanimously that all presented news stories except the negative control cases portrayed misidentified functional movement or seizure disorders. The interrater agreement and average diagnostic confidence were high.

**Conclusions:** Functional neurological disorders are often wrongly considered a rare medical curiosity of the past. However, these findings suggest that, while they are largely absent from public discourse, they often appear in the news incognito, hiding in plain sight.

*J Neuropsychiatry Clin Neurosci* 2019; 31:361–367;  
doi: 10.1176/appi.neuropsych.19010025

There is a reason why functional neurological disorder (FND), also known as conversion disorder and (in the past) hysteria, has not shed its mythology and stigma. Unlike other historically misunderstood illnesses, such as epilepsy or AIDS, FND cannot be detected using electroencephalography or immunoassays. Instead, routine laboratory and imaging findings are typically normal, so for large parts of the medical community and the public, FND is still considered an elusive, “medically unexplained” disorder, diagnosed by exclusion, almost indistinguishable from malingering. These assumptions, however, are wrong. Whether manifesting as a movement disorder or seizures, FND can be identified with confidence by physicians on the basis of phenotype-specific clinical signs (Table 1) (1–3). These tried and tested signs have been incorporated into validated sets of diagnostic criteria. In fact, when the diagnosis of FND is made by a specialist (in

around 15% of all neurology presentations) it is almost invariably accurate and remains stable over time (4, 5).

This discrepancy is mirrored in a more general misunderstanding of FND by the public. Long marred by social stigma, FND has been a confusing and shameful diagnosis for many patients. Thus, it is not surprising that patients can be reluctant to accept a diagnosis of FND. Physicians, on the other hand, who are often uncertain about their diagnosis by exclusion, will often repeat tests and scans until a false positive or unrelated finding redirects the course of treatment. At this point alternative, less evidence-based explanations may be offered by well-meaning practitioners of different persuasions. Patients with FND can find themselves on tortured journeys through a multitude of clinics, and the eventual diagnosis of FND—especially if explained poorly—is often met with skepticism. Sometimes these patient journeys appear in social

**TABLE 1. Movement disorders portrayed in selected news media stories<sup>a</sup>**

Case	Year	Age (years)/sex	Diagnosis in news story	Rated functional		Rated "organic"		Selected positive signs <sup>c</sup>
				Raters (%)	Mean confidence <sup>b</sup>	Raters (%)	Mean confidence <sup>b</sup>	
1	2016	36/Male	Dystonia, dystonic storms	100	9.4	0	—	Asynchronous clonic movements; rhythmic pelvic movements; variable tremulous movement; abnormal movements seem activated by a light tactile stimulus
2	2012	16/Female	Lyme disease	100	9.9	0	—	Noneconomic posture while walking; extreme variability; incongruence; attention modulation
3	2016	NA/Male	Tremor, medication-induced	100	9.9	0	—	Whack-a-mole sign; tremor in different directions; volitional control to stop tremor
4	2017	27/Female	Dystonia, drug-induced	100	9.7	0	—	Lip-pulling sign; huffing and puffing sign; crouched gait; mixed and incongruent phenomenology
5	2017	NA/Female	Unnamed condition	100	7.9	0	—	Huffing and puffing sign; clenching fist in absence of spasticity/parkinsonism; gasping for air but not during speech; dragging gait; bilateral fixed ankle posturing with inversion; fixed dystonia
6	2013	41/Female	Dystonia	100	9.2	0	—	"Other Babinski" sign; lip-pulling sign; symmetry of platysma contraction
7	2016	NA/Female	Surgery-induced tremor	90	7.8	10	8.0	Variability of frequency and amplitude of tremor; pause with ballistic movement; distractible
8 <sup>d</sup>	2015	35/Male	Dystonia	0	—	100	9.5	Striatal postural deformities; patterned dystonic postures; scoliotic dystonic trunk abnormality

<sup>a</sup> NA=information not available.

<sup>b</sup> 0–10 confidence scale (0=no confidence, 10=absolutely confident).

<sup>c</sup> Raters were prompted to report any signs that influenced their diagnostic decision; selected signs identified by one or more raters are reported.

<sup>d</sup> Control case.

media, where misidentified FND is showcased unknowingly. On YouTube, for example, two-thirds of the most viewed movement disorder videos uploaded by patients have been found to show functional movement disorders (6). Surprisingly, however, news articles portraying and discussing FND are a rarity. Are affected patients shunning the limelight, or are journalists and the public not interested in FND? A few high-profile cases of misidentified FNDs in news stories (7–9) have suggested a different interpretation: FND is hiding in plain sight, wrongly attributed to an alternative neurological disorder or labeled a medical “mystery” (8). To test this hypothesis we conducted an informal observational study.

**METHODS**

News stories were identified by the study coordinators (S.P., T.R.N., J.S.) through nonsystematic online searches using

Google’s video search and the online search function of news outlets. Implementing a strictly formulated systematic search strategy was infeasible due to the vastness of online media content and the variability of terminology encountered in such articles. The following criteria were used to select appropriate news stories: English language; major media outlet; content available online; published within the last 5 years; available material (including video or still images) sufficiently detailed to offer independent experts an opportunity to make a diagnostic judgment; case not already subject to wide public debate; neurological symptoms portrayed likely to be functional based on positive criteria (1–3); functional (psychogenic) etiology not acknowledged. Ultimately, 13 news stories that fulfilled all criteria were selected. The news stories came from the following sources: BBC (N=4), CNN (N=3), FOX (N=1), *Las Vegas Review-Journal* (N=1), *The Telegraph* (N=1), ABC

News (N=1), *Coventry Telegraph* (N=1), and *The Guardian* (N=1).

To test whether these news stories indeed portrayed unacknowledged or misidentified FND, they were presented to a group of expert raters. The news stories were split into two groups: seizures and movement disorders. One news story was featured in both categories (case 5 in seizure group and case 2 in movement disorders group), since both symptoms were reported and portrayed. For each category, a news story showing a relatively rare neurological disorder other than FND was also added as a negative control case to counteract the inherent rater bias of participating in a study on FND in media. These control cases were otherwise chosen using the same selection criteria (sources: FOX and KGW). Raters were told that there would be at least one news story featuring a neurological disorder other than FND to encourage critical consideration of competing etiologies.

Ten movement disorders specialists and ten epileptologists representing a broad field of clinical and research expertise were asked to participate in the study as expert raters. Each rater independently completed a form with instructions and a table including eight news stories (seven per group, including one case that had both movement disorder and seizures, plus one control case). Raters were asked to judge whether the symptoms seen in each news story were most likely related to a functional disorder or due to an alternative neurological disease such as primary dystonia or epilepsy. Information from the article text could also be considered. Since dual diagnosis is possible, the task was to decide which etiology was most likely to explain the symptoms to a large extent or completely and provide a dichotomous answer. Raters were then asked to indicate their diagnostic confidence for each case on a numerical 0–10 confidence scale (0=no confidence, 10=absolutely confident). Lastly, raters were asked to freely report specific signs or features that influenced their diagnostic decisions in order to encourage decisions on the basis of identifiable positive clinical signs.

Although all patients were presumed to have given consent to be portrayed in publicly accessible media outlets, a re-diagnosis without face-to-face consultation, while clinically possible in some cases, is ethically problematic (9); therefore, we are not reporting the source details of the specific news stories. The original rating forms, including the sources of news stories (URL links), were made available to the journal editors and peer reviewers but are not referenced in this article. No clinically obtained patient data were used in this study, so ethics committee approval was not sought.

To calculate interrater agreement, Cohen's kappa ( $\kappa$ ) was calculated according to the Fleiss-Cuzick extension (10) using StatsDirect statistical software (Cheshire, United Kingdom) and interpreted as poor, fair, moderate, good, or very good according to categorization by Landis and Koch (11).

## RESULTS

News stories in the movement disorders category are summarized in Table 1. In six of the seven cases with presumed functional movement disorders, agreement among raters was 100% with an average confidence rating of 9.3 out of 10. In one case, there was disagreement, with nine of 10 raters judging it to be a functional movement disorder with an average confidence rating of 7.8/10. The negative control (case 8) was unanimously identified as "organic" (mean confidence rating, 9.5). The overall interrater agreement for the movement disorders category including the control case was  $\kappa=0.89$  (very good; 95% CI=0.79–1.00,  $p<0.0001$ ).

News stories in the seizure category are summarized in Table 2. In five of the seven cases with presumed dissociative attacks, agreement among raters was 100% with an average confidence rating of 8.9 out of 10. In two of the cases, there was some disagreement, with nine of 10 raters judging cases 1 and 6 to be a manifestation of FND, with average confidence ratings of 8.6 and 5.7, respectively. The negative control (case 8) was unanimously identified as epileptic (mean confidence rating, 8.5). The overall interrater agreement for the seizure category including the control case was  $\kappa=0.80$  (very good; 95% CI=0.70–0.91,  $p<0.0001$ ).

## DISCUSSION

Our study identified 13 highly probable cases of FND in news media stories that were not recognized as such; 11 of these cases were reported as other medical conditions. Cases were divided into two categories (seizures and movement disorders) and presented to raters along with one negative control case to counteract bias. In both groups, raters confidently and mostly unanimously judged that the presentations were indeed best explained by FND and not, as often suggested in the news stories, neurological symptoms caused by diseases such as Lyme disease or epilepsy.

Dissociative (non-epileptic) seizures and functional movement disorders are common forms of FND. The reliability of video-based remote diagnosis has been investigated for both disorders. Experienced epileptologists can correctly identify dissociative seizures in about 85% of cases from video alone (12, 13). The more experience physicians have with dissociative seizures, the higher the rate of correct diagnosis via video (14). The diagnosis of functional movement disorders is based on positive clinical features such as distractibility, inconsistency, and incongruence with other neurological diseases and can be aided by phenotype-specific signs such as Hoover's sign or tremor entrainment (1, 3). Interrater agreement on video-based diagnosis has been variable and appears to be dependent on the difficulty of cases (15, 16). However, as yet there is no laboratory test to serve as a gold standard and validate clinical judgment of experts (17). Our specifically preselected videos and articles can be assumed to represent particularly clear-cut cases of functional movement disorders, which probably explains

**TABLE 2. Seizures portrayed in selected news media stories<sup>a</sup>**

Case	Year	Age (years)/sex	Diagnosis in news story	Rated psychogenic		Rated "organic"		Selected positive signs <sup>c</sup>
				Raters (%)	Mean confidence <sup>b</sup>	Raters (%)	Mean confidence <sup>b</sup>	
1	2017	19/Female	Epilepsy	90	8.6	10	6.0	Eye closure; back arching; eyes roll up; high variability of events; rapid recovery
2	2015	35/Female	Epilepsy	100	9.4	0	—	Eyes closed; waxing/waning; body thrusting; movements mild with no suggestion of increased tone
3	2016	23/Male	Unknown disease	100	7.6	0	—	Side-to-side head shaking; forced eye closure; rolling side to side; markedly variable manifestations; semipurposeful movements
4	2015	21/Female	Clinically dead due to POTS	100	9.4	0	—	Buildup of the event with hyperventilation; prolonged floppy unresponsiveness
5	2012	16/Female	Seizures due to Lyme disease	100	9.5	0	—	Ictal crying; asynchronous low-amplitude tremulous shoulder movements
6	2016	16/Female	Seizures	90	5.7	10	2.0	Sudden loss of consciousness with intense emotion; prolonged unresponsiveness; no apparent premonitory symptoms or signs
7	2015	21/Female	Seizures due to mast cell disease	100	8.4	0	—	Closed eyes; asynchronous side-to-side head and shoulder movements
8 <sup>d</sup>	2016	10/Female	Seizures	0	—	100	8.5	Eyes open; eye deviation to the side; rhythmic, synchronous tonic-clonic movements

<sup>a</sup> POTS=postural orthostatic tachycardia syndrome.

<sup>b</sup> 0–10 confidence scale (0=no confidence, 10=absolutely confident).

<sup>c</sup> Raters were prompted to report any signs that influenced their diagnostic decision; selected signs identified by one or more raters are reported.

<sup>d</sup> Control case.

the high interrater agreement in our study. Similarly, a study in which experts rated functional movement disorders in popular YouTube videos yielded very high interrater agreement (6).

There are various potential reasons for the misrepresentation of FND in news media. A major factor is probably the high rate of underdiagnosis of these disorders by physicians. Around 30% of patients referred to epilepsy centers with refractory seizures do not have epilepsy, and a large portion of those have dissociative seizures (18). The high rate of misdiagnosis is furthermore evident in the exceptionally long diagnostic latency of about 5–10 years for those who are eventually diagnosed correctly as experiencing dissociative seizures (18, 19). While there are no studies quantifying the rate of misdiagnosis of functional movement disorders as other neurological diseases, FNDs in general regularly figure in statistics of misdiagnoses of other neurological disorders. In a study of 110 patients misdiagnosed as having multiple sclerosis, the underlying reason was FND in 11% and fibromyalgia in 15% (20). In stroke medicine, FNDs account for 28%–47% of all

retrospectively recognized stroke mimics mistakenly treated with intravenous tissue plasminogen activator (21, 22). Naturally, when FND is missed by neurologists who typically worry more about missing structural than functional disorders, neither patients nor journalists should be expected to identify it in human interest stories. In addition, patients with unresolved diagnoses are arguably more likely to seek redress or validation through the media.

Even when FND is correctly recognized by a physician, patients can often be left unsure or unaccepting about the essence and certainty of their diagnosis (23). Neurologists often hold negative views on FND (24), find little about FND in their textbooks or training curricula (25), have concerns about diagnostic certainty or malingering (26), and often assume a pre-emptively defensive stance when communicating the diagnosis (27). Patients are often presented with outmoded or overly narrow versions of psychosomatic models that are liable to be interpreted in offensive terms (28). Many wonder why there is no radiologic or laboratory proof of diagnosis, and some hold on to strong views about alternative diagnoses (23, 29). Crucially, physicians and

therapists need to help patients and the public understand the central role of positive clinical signs in the diagnostic process (1–3). High-tech brain scans and novel antibodies make for impressive headlines, but they are not how movement disorders or seizures are primarily diagnosed. Neurologists need to communicate the reliability of clinical signs and syndrome classifications in order to get across why FND is not a dustbin diagnosis, but a common, well-recognized and potentially treatable condition. Finally, the lack of established treatment services in many places might also explain why FND patients are prone to seek help and validation online or through news media (6). Historically, there has been a distinct absence of positive or neutral public awareness of FND, which may underlie some of these issues and is certainly a factor on its own. Thankfully this is beginning to change.

FND Hope ([www.fndhope.org](http://www.fndhope.org)) and FND Action ([www.fndaction.org.uk](http://www.fndaction.org.uk)) are examples of newly established patient-led organizations promoting awareness of the disorder and its treatment. In a few rare instances, individuals with FND have been profiled in informed and positive news stories (30–32). The Movement Disorders Society has a new Functional Movement Disorders Study Group to aid international collaboration, and the International League Against Epilepsy has an active Psychogenic Non-Epileptic Seizures Task Force. The Functional Neurological Disorder Society will be inaugurated shortly, providing a platform and resource for all healthcare professionals, scientists, students, and members of the lay public who are interested in FND ([www.fndsociety.org](http://www.fndsociety.org)). Lifting the stigma and mystery surrounding FND will require a shift in attitudes, both medical and societal. Psychiatrists, neurologists, psychologists, physiotherapists, occupational therapists, and everyone else who is involved in caring for patients with FND need to work together toward improving health care provision for this common and disabling disorder. The medical community needs to engage in interdisciplinary and collaborative publicity efforts with patients, artists, journalists, and policy makers in order to break the cycle of misconceptions and misrepresentation and lead FND back out of hiding.

#### AUTHOR AND ARTICLE INFORMATION

The Department of Neurology, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum, Bochum, Germany (Popkirov); the Section of Cognitive Neuropsychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London (Nicholson); the Department of Neurology, Radboud University Medical Centre, Donders Institute for Brain, Cognition, and Behaviour, Nijmegen, the Netherlands (Bloem); the Institute of Medical and Biomedical Education, St. George's University of London and Atkinson Morley Regional Neuroscience Centre, St. George's University Hospitals NHS Foundation Trust, London (Cock); the Department of Clinical Neurosciences, Western General Hospital, Edinburgh, United Kingdom (Derry); the Department of Neurology, University of Otago, Christchurch, New Zealand (Duncan); the Department of Neurology, Edward B. Bromfield Epilepsy Program, Brigham and Women's Hospital, Harvard Medical School, Boston (Dworetzky); the Institute of Molecular and Clinical Sciences, St. George's University of London (Edwards, Morgante); the Department of

Neurology, Gardner Family Center for Parkinson Disease and Movement Disorders, University of Cincinnati (Espay); the Human Motor Control Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Md. (Hallett); the Morton and Gloria Shulman Movement Disorders Clinic and Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto (Lang); Queen Elizabeth University Hospital, University of Glasgow, Glasgow, United Kingdom (Leach); the Mater Centre for Neurosciences and School of Medicine, University of Queensland, Brisbane, Australia (Lehn); the Institut de Neurosciences des Systèmes, INSERM, Aix-Marseille Université, Marseille, France; the Department of Clinical Neurophysiology, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France (McGonigal); the Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy (Morgante); the Departments of Neurology and Psychiatry, Functional Neurology Research Group, Massachusetts General Hospital, Harvard Medical School, Boston (Perez); the Academic Neurology Unit, University of Sheffield, Royal Hallamshire Hospital, Glossop Road, Sheffield, United Kingdom (Reuber); the Institute of Psychiatry, Psychology and Neuroscience, Kings College London (Richardson); the Department of Neurology, Alan Richens Epilepsy Unit, University Hospital of Wales, Cardiff, United Kingdom (Smith); the HY-GEIA Hospital, Athens, Greece (Stamelou); the Neurology Clinic, Philipps University Marburg, Marburg, Germany (Stamelou); the University of Athens, Greece (Stamelou); the Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Tijssen); the Neurology Unit, Movement Disorders Division, University of Verona, Verona, Italy (Tinazzi); and the Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom (Carson, Stone).

Send correspondence to Dr. Popkirov ([popkirov@gmail.com](mailto:popkirov@gmail.com)).

This article presents independent research funded by the NIHR. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health.

Dr. Nicholson is supported by a National Institute for Health Research (NIHR) Clinician Scientist Award. Dr. Bloem serves as Associate Editor of the *Journal of Parkinson's Disease* and on the editorial board of *Practical Neurology*; he has received honoraria for his service on the scientific advisory boards of AbbVie, Biogen, UCB, and Zambon; he has received speaker's fees from AbbVie, Bial, and Zambon; and he has received research support from AbbVie, the Hersenstichting Nederland, Horizon 2020, the Michael J. Fox Foundation, the Netherlands Organization for Scientific Research, the Parkinson's Foundation, the Parkinson Vereniging, the Stichting Parkinson Fonds, Topsector Life Sciences and Health, UCB, and Verily Life Sciences. Dr. Cock has received fees from Eisai Europe Ltd, European Medicines Agency, Sage Pharmaceuticals Ltd, UCB Pharma Ltd, and the United Kingdom Epilepsy Nurse Specialist Association; she has received grant support from the NIH Institute of Neurological Disorders and Stroke; and she has received nonfinancial support from the Epilepsy Certification (education) Task Force, the European Academy of Neurology, the International League Against Epilepsy, Special Products Ltd, and the Status Epilepticus Classification Task Force. Dr. Dworetzky has received royalties from Oxford University Press. Dr. Edwards has received royalties from Oxford University Press; and he has received honoraria from Boehringer Ingelheim and Merz Pharma. Dr. Espay has served on the scientific advisory boards of AbbVie, Acadia, Acorda, Impax, Lundbeck, Neuroderm, Osmotica Pharmaceutical, Sunovion, Teva Pharmaceuticals, and US WorldMeds; he has received honoraria from AbbVie, Acadia, the American Academy of Neurology, Lundbeck, the Movement Disorders Society, Sunovion, UCB, and US WorldMeds; he has received grant support from Great Lakes Neurotechnologies, the Michael J. Fox Foundation, and NIH; and he has received royalties from Cambridge University Press, Lippincott Williams and Wilkins, and Springer. Dr. Hallett may accrue revenue for U.S. patents (#6,780,413 B2 and #7,407,478); he has received license fees from NIH (from Brainsway); he serves on the medical advisory boards of Brainsway and Cala Health; he receives royalties and/or

honoraria from Cambridge University Press, Springer, Elsevier, and Oxford University Press; his research at NIH is largely supported by the NIH Intramural Program; he has received supplemental research funds from Allergan, Cala Health, Medtronic, and Merz; and he serves on the editorial boards of *Movement Disorders Clinical Practice*, *Brain Stimulation*, the *Journal of Clinical Neurophysiology*, *Translational Neurodegeneration*, the *Journal of Parkinson's Disease*, *Medical Problems of Performing Artists*, *Tremor and Other Hyperkinetic Movements*, the *Journal of Movement Disorders*, *Functional Neurology*, and *Neurology and Clinical Neurophysiology*. Dr. Lang has served as a consultant for AbbVie, Acorda, Biogen, Corticobasal Degeneration Solutions, Janssen, Jazz Pharma, Kallyope, Merck, Paladin, Sun Pharma, and Theravance; he has received honoraria from AbbVie, Medichem, Medtronic, Sunovion, and Sun Pharma; he has received grant support from Brain Canada, the Canadian Institutes of Health Research, Corticobasal Degeneration Solutions, the Edmond J. Safra Philanthropic Foundation, the Michael J. Fox Foundation, the National Parkinson Foundation, Parkinson Society Canada, the Ontario Brain Institute, and the W. Garfield Weston Foundation; and he has received royalties from Cambridge University Press, Elsevier, Johns Hopkins University Press, Saunders, and Wiley-Blackwell. Dr. Leach has received honoraria from Biogen, GW Pharmaceuticals, and UCB Pharma. Dr. Morgante has served as a consultant to or on the scientific advisory board of Bial and Merz; she has received speaker's honoraria from AbbVie, Bial, Chiesi Farmaceutici, Medtronic, Merz, UCB, and Zambon; she serves on the editorial boards of *Movement Disorders and Movement Disorders Clinical Practice*, and she has received royalties from Springer. Dr. Perez has received research support from Massachusetts General Hospital, NIMH, and the Sidney R. Baer Jr. Foundation; and he has received honoraria from the American Academy of Neurology, Harvard Medical School, the Movement Disorder Society, and the Toronto Western Hospital. Dr. Reuber has received an unrestricted educational grant from UCB Pharma; he has received compensation from Elsevier for editorial work for *Seizure-European Journal of Epilepsy*; and he receives royalties from Oxford University Press. Dr. Richardson has received research funding from the Canadian Institutes of Health Research, Epilepsy Research UK, the Engineering and Physical Sciences Research Council, the European Commission, Innovative Medicines Initiative, the Medical Research Council, NIHR, and Xenon Pharma; and he has served as a consultant to Xenon Pharma. Dr. Stamelou serves on the editorial board of *Movement Disorders*; she has received research and grant support from Biogen and Parkinson's Progression Markers Initiative; she has received speaker and travel honoraria from AbbVie, Biogen, the International Parkinson and Movement Disorder Society, and Specifar; she has served on the advisory board of Biogen; and she has received royalties from Cambridge University Press and Oxford University Press. Dr. Tijssen is supported by Fonds Nuts-Ohra, Fonds Psychische Gezondheid, the Gossweiler Foundation, Hersenstichting, the Parkinson Patienten Vereniging, Phelps Stichting, Prinses Beatrix Fonds, Stichting Beatrix Kinderziekenhuis, and Stichting Wetenschapsfonds Dystonie Vereniging; and she has received unrestricted educational grant support from Acthelion, Allergan, Ipsen, Medtronic, and Merz. Dr. Tinazzi has received speaker's honoraria from AbbVie, UCB Pharma, and Zambon. Dr. Carson provides independent testimony in court on a range of topics that include functional symptoms. Dr. Stone provides independent testimony in court on a range of topics that include functional disorders; he receives royalties from UpToDate; and he is owner of a nonprofit self-help website ([www.neurosymbols.org](http://www.neurosymbols.org)). The other authors report no financial relationships with commercial interests.

Received January 23, 2019; revision received February 26, 2019; accepted March 5, 2019; published online May 23, 2019.

## REFERENCES

1. Espay AJ, Aybek S, Carson A, et al: Current concepts in diagnosis and treatment of functional neurological disorders. *JAMA Neurol* 2018; 75:1132–1141. doi: 10.1001/jamaneurol.2018.1264

2. Avbersek A, Sisodiya S: Does the primary literature provide support for clinical signs used to distinguish psychogenic nonepileptic seizures from epileptic seizures? *J Neurol Neurosurg Psychiatry* 2010; 81:719–725
3. Espay AJ, Lang AE: Phenotype-specific diagnosis of functional (psychogenic) movement disorders. *Curr Neurol Neurosci Rep* 2015; 15:32
4. Stone J, Carson A, Duncan R, et al: Symptoms “unexplained by organic disease” in 1144 new neurology out-patients: how often does the diagnosis change at follow-up? *Brain* 2009; 132: 2878–2888
5. Stone J, Smyth R, Carson A, et al: Systematic review of misdiagnosis of conversion symptoms and “hysteria.” *BMJ* 2005; 331: 989
6. Stamelou M, Edwards MJ, Espay AJ, et al: Movement disorders on YouTube: caveat spectator. *N Engl J Med* 2011; 365:1160–1161
7. Novella S: The dystonia flu-shot case. <https://theness.com/neurologicablog/index.php/the-dystonia-flu-shot-case>
8. Susan Dominus: What happened to the girls in Le Roy. *New York Times Magazine*, March 7, 2012. <https://www.nytimes.com/2012/03/11/magazine/teenage-girls-twitching-le-roy.html>
9. Wardrope A, Reuber M: Diagnosis by documentary: professional responsibilities in informal encounters. *Am J Bioeth* 2016; 16: 40–50
10. Fleiss JL, Cuzick J: The reliability of dichotomous judgements: unequal numbers of judges per subject. *Appl Psychol Meas* 1979; 3: 537–542
11. Landis JR, Koch GG: The measurement of observer agreement for categorical data. *Biometrics* 1977; 33:159–174
12. Beniczky SA, Fogarasi A, Neufeld M, et al: Seizure semiology inferred from clinical descriptions and from video recordings. How accurate are they? *Epilepsy Behav* 2012; 24:213–215
13. Wasserman D, Herskovitz M: Epileptic vs psychogenic nonepileptic seizures: a video-based survey. *Epilepsy Behav* 2017; 73: 42–45
14. Ristić AJ, Mijović K, Bukumirić Z, et al: Differential diagnosis of a paroxysmal neurological event: Do neurologists know how to clinically recognize it? *Epilepsy Behav* 2017; 67:77–83
15. Morgante F, Edwards MJ, Espay AJ, et al: Diagnostic agreement in patients with psychogenic movement disorders. *Mov Disord* 2012; 27:548–552
16. van der Salm SM, de Haan RJ, Cath DC, et al: The eye of the beholder: inter-rater agreement among experts on psychogenic jerky movement disorders. *J Neurol Neurosurg Psychiatry* 2013; 84:742–747
17. van der Salm SM, van Rootselaar AF, Cath DC, et al: Clinical decision-making in functional and hyperkinetic movement disorders. *Neurology* 2017; 88:118–123
18. Reuber M, Pukrop R, Bauer J, et al: Outcome in psychogenic nonepileptic seizures: 1 to 10-year follow-up in 164 patients. *Ann Neurol* 2003; 53:305–311
19. Hamilton JC, Martin RC, Stone J, et al: The cost and burdens of psychogenic nonepileptic seizures in context: PNES and other conversion disorders, in *Gates and Rowan's Nonepileptic Seizures*, 4th ed. Edited by LaFrance W Jr, Schachter S. Cambridge, United Kingdom, Cambridge University Press, 2019, pp 31–43
20. Solomon AJ, Bourdette DN, Cross AH, et al: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. *Neurology* 2016;87(13):1393–1399.
21. Lewandowski C, Mays-Wilson K, Miller J, et al: Safety and outcomes in stroke mimics after intravenous tissue plasminogen activator administration: a single-center experience. *J Stroke Cerebrovasc Dis* 2015; 24:48–52
22. Zinkstok SM, Engelter ST, Gensicke H, et al: Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. *Stroke* 2013; 44:1080–1084

23. Stone J, Carson A, Hallett M: Explanation as treatment for functional neurologic disorders. *Handb Clin Neurol* 2016; 139: 543–553
24. Evans RW, Evans RE: A survey of neurologists on the likeability of headaches and other neurological disorders. *Headache* 2010; 50: 1126–1129
25. Stone J, Hewett R, Carson A, et al: The “disappearance” of hysteria: historical mystery or illusion? *J R Soc Med* 2008; 101: 12–18
26. Kanaan R, Armstrong D, Barnes P, et al: In the psychiatrist’s chair: how neurologists understand conversion disorder. *Brain* 2009; 132: 2889–2896
27. Monzoni CM, Duncan R, Grünewald R, et al: How do neurologists discuss functional symptoms with their patients: a conversation analytic study. *J Psychosom Res* 2011; 71:377–383
28. Stone J, Wojcik W, Durrance D, et al: What should we say to patients with symptoms unexplained by disease? The “number needed to offend”. *BMJ* 2002; 325:1449–1450
29. Whitehead K, Kandler R, Reuber M: Patients’ and neurologists’ perception of epilepsy and psychogenic nonepileptic seizures. *Epilepsia* 2013; 54:708–717
30. Licence J: How am I running when I can’t walk? <https://vimeo.com/149937489>
31. Walk J: His baffling illness solved, Jason Lindsley back on Lampeter-Strasburg sidelines with “no limitations.” [http://lancasteronline.com/sports/football/highschool/his-baffling-illness-solved-jason-lindsley-back-on-lampeter-strasburg/article\\_94da443c-935c-11e7-8b61-b36422520801.html](http://lancasteronline.com/sports/football/highschool/his-baffling-illness-solved-jason-lindsley-back-on-lampeter-strasburg/article_94da443c-935c-11e7-8b61-b36422520801.html)
32. Stone J: Functional neurological disorder (FND): a patient’s guide. <https://www.neurosymbols.org/video/4594371748>